Zhitong Finance App News, Hewang Pharmaceutical (00013.HK) announced today the launch of the phase III phase III study of surufatinib (surufatinib) in combination with camrelizumab (camrelizumab), albumin-binding paclitaxel (nab-paclitaxel), and gemcitabine (gemcitabine) for first-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDAC). The first patient received the first dose on December 30, 2025.

Zhitongcaijing · 5d ago
Zhitong Finance App News, Hewang Pharmaceutical (00013.HK) announced today the launch of the phase III phase III study of surufatinib (surufatinib) in combination with camrelizumab (camrelizumab), albumin-binding paclitaxel (nab-paclitaxel), and gemcitabine (gemcitabine) for first-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDAC). The first patient received the first dose on December 30, 2025.